This page contains a Flash digital edition of a book.
Lung Cancer


The Evolving Role of Chemotherapy and Predictive Markers in Early-stage Non-small-cell Lung Cancer


Eric W Humke1 and Heather Wakelee2


1. Instructor of Medicine; 2. Assistant Professor of Medicine, Department of Medicine, Division of Oncology, Stanford Cancer Center, Stanford University School of Medicine


Abstract


Lung cancer continues to be the leading cause of cancer mortality worldwide. The utility of traditional chemotherapy has reached a plateau in both the metastatic and adjuvant settings. However, we have entered an era of better targeting of both traditional cytotoxic agents and newer compounds for select subsets of patients based on genetic analysis of the tumour. Substantial evidence supports the use of adjuvant chemotherapy in both stage II and stage III non-small-cell lung cancer (NSCLC), but it remains unclear which combination of either traditional or targeted therapies will work best for an individual patient. The use of chemotherapy and targeted therapies in patients with resected stage I NSCLC remains controversial because we cannot predict who benefits from its usage. This article focuses on the evolving role of predictive biomarkers in early-stage NSCLC and summarises the trials that are prospectively evaluating the use of those biomarkers to individualise treatment of NSCLC.


Keywords Early-stage non-small-cell lung cancer, chemotherapy, predictive markers


Disclosure: Eric W Humke has no conflicts of interest to declare. Heather Wakelee has received research funding from Genentech BioOncology, Bayer, AstraZeneca, Eli Lilly and Company, Novartis and Pfizer. Received: 23 March 2010 Accepted: 17 February 2011 Citation: European Oncology & Haematology, 2011;7(2):109–15 Correspondence: Heather Wakelee, Thoracic Oncology, 875 Blake Wilbur Drive, Room 2233, MC 5826 Stanford, CA 94305, US. E: hwakelee@stanford.edu


Lung cancer is the leading cause of cancer mortality worldwide. Surgery remains the optimal treatment for early-stage non-small-cell lung cancer (NSCLC); however, five-year survival rates for resected NSCLC without additional treatment range from 20 to 40% for stage IIIA disease to 70 to 80% for stage IA disease.1


Mortality occurs most


commonly from recurrences at sites outside the lung, suggesting that the cancer had spread before surgery.


These analyses are still based on empiric treatment and do not address the question of who will benefit the most from therapy and who may be harmed. The ultimate goal of adjuvant NSCLC treatment is to predict which patients will benefit from the use of chemotherapy, targeted therapy and radiation therapy, and to individualise therapy based on the patient’s tumour characteristics, including histology and genetic analysis. Recently, trials have begun to use novel biomarkers as a first step towards individualised adjuvant therapy.


In this article, we will give a brief historical background on the use of chemotherapy in the adjuvant setting, followed by previously investigated biomarkers to guide adjuvant therapy and end with a discussion of ongoing clinical trials to address the important question of how to personalise adjuvant therapy.


© TOUCH BRIEFINGS 2011


The goal of systemic therapy in patients with resected NSCLC is to eradicate the prior seeded micrometastases to improve overall survival. Several clinical trials and meta-analyses have shown improved survival in resected NSCLC with different combinations of chemotherapy.2–7


History of the Use of Chemotherapy in Resected Non-small-cell Lung Cancer Initial use of chemotherapy in NSCLC was only for metastatic disease. In 1991, an international panel recommended against the routine use of adjuvant chemotherapy outside of clinical trials.8


Four years later a


meta-analysis was undertaken to investigate the role that chemotherapy after surgery had played in trials up to that point.9 Fourteen trials were evaluated and the meta-analysis showed a 5% improvement in five-year survival but failed to reach statistical significance. Owing to this encouraging result and the established benefit of adjuvant chemotherapy in multiple other solid tumours, several follow-up studies were initiated.


The follow-up clinical trials validated the use of adjuvant chemotherapy in resected NSCLC.10


The major adjuvant trials are


beyond the scope of this article; however, they are highlighted in Table 1.


Although not all the trials were positive, a large meta-analysis of the data has reaffirmed the use of adjuvant chemotherapy. The Lung adjuvant cisplatin evaluation (LACE) meta-analysis was conducted to identify treatment options for post-operative chemotherapy.5


Data


from 4,584 patients were pooled from the five largest adjuvant trials (Adjuvant lung project Italy [ALPI],11 Association [ANITA],3 cancer trial [IALT]2


Big lung trial [BLT],12 and JBR.104 corresponding to a five-year overall survival benefit of 5.4% from 109


Adjuvant International Trialist International adjuvant lung


). The overall hazard ratio (HR) was 0.89,


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68